Closing arguments underway in Shafia family murder trial

There are simply too many unknowns to be able to convict a Montreal couple of four counts of first-degree murder in the deaths of their daughters and other polygamous wife, a jury in eastern Ontario heard Tuesday in a case prosecutors allege is a so-called honour killing.

The Crown alleges Mohammad Shafia, 58, his wife Tooba Yahya, 42, and their son Hamed, 21, killed Hamed’s three sisters and Shafia’s other wife. The bodies were found June 30, 2009 in a car at the bottom of a canal in Kingston, Ont., but the Crown did not present evidence specifically detailing how it believes the four died.

The Crown has suggested it believes they were dead before the car plunged into the water, but in his closing address Tuesday Shafia’s lawyer told the jury they can’t rely on theories.

“You don’t know where, you don’t know how, you don’t know when that happened, you don’t know who would have been involved in that and you don’t have an explanation that there was simply no time for a murder,” Peter Kemp said.

“The Crown has the burden of establishing his guilt beyond a reasonable doubt…With all these unknowns it’s only speculation that can provide answers and speculation, ladies and gentlemen, is not proof beyond a reasonable doubt. Mohammad Shafia has not had the case proven against him and should be acquitted.”

Yahya’s lawyer, David Crowe, also told the jury there are too many unanswered questions and his client should be found not guilty.

In his closing remarks, Kemp outlined a possible murder scenario, with the accused luring the victims out of the car one by one, drowning them in a nearby pond, stashing the bodies off to the side so each subsequent victim wouldn’t see them, then carrying four bodies back to the car, before manoeuvring the vehicle into place.

Kemp estimated how long each step would take and said there was not nearly enough time for all that activity before cellphone records indicate the family’s next known whereabouts.

Both Crowe and Kemp said the Crown’s evidence concerning motive is flimsy.

Court has heard Shafia had a troubled relationship with his teenage daughters, but Crowe told the jury Shafia had forgiven Zainab, 19, for her transgressions — namely dating, marrying then quickly divorcing her Pakistani boyfriend — and that he wasn’t aware before her death that Sahar, 17, was dating.

The conflict with Geeti, 13, mostly related to school attendance, Crowe said. If Shafia truly wanted his first wife Rona Amir Mohammad, 52, out of his life, he wouldn’t have brought her when the family immigrated to Canada in 2007, Kemp said.

Crowe went over evidence from an expert on “honour killings” and said this case does not fit.

“The concept of honour killing has no application to the events before you,” Crowe said. “It should be disregarded in its totality when you’re deliberating.”

The jury is expected to begin its deliberations Friday. The judge told the jury that Hamed’s lawyer would address them Wednesday, followed by the Crown, whose remarks would spill into Thursday. Judge Robert Maranger said he expects to give the jury its final instructions Thursday and Friday.

Crowe suggested that a version of events Hamed laid out four months after their arrest placing only himself at the scene is legitimate. Police wiretaps indicate that Yahya, at least, did not know how her daughters and Rona had died, Crowe said.

“God so took away their common sense,” Yahya is heard saying after police showed the family the scene on July 18, 2009. “They didn’t think. They had no business there.” Shafia replied, “God knows and his works.”

Hamed told a private investigator hired on the sly by Shafia that he had seen his sisters and Rona drive out of a motel the family was staying in during a road trip. He said he followed in the family’s other vehicle, a Lexus, and they ended up at the locks, where he rear-ended them accidentally and urged them to turn around. As he was picking up some pieces of a broken head light, he heard a splash, he said. The car had plunged into the water.

Hamed said he sounded the horn of the Lexus as a call for help, then took a rope from the trunk and dangled it in the water. Seeing no signs of life, he said he drove straight home to Montreal, calling police only to report an accident he later admitted he staged to mask damage to the Lexus.

The wiretaps, which captured Shafia spewing vitriol about his dead daughters, calling them treacherous and whores, and invoking the devil to defecate on their graves were a focal point of the trial.

Crowe called the language clearly “disturbing,” and said it needed to be explained.

The defence says the phrase about the devil is common in Afghanistan, and what the wiretaps show is Shafia blowing off steam after discovering pictures of Sahar in a bikini and finding out she didn’t tell him she had a boyfriend. The Crown contends that was all discovered before the deaths and gave Shafia motive.

What’s notable about the wiretap evidence is what’s absent, Crowe told the jury.

“At no point do the intercepts say, ‘We drowned them,'” he said. “At no point do the intercepts say, ‘We have regained our honour by drowning them.'”

Kemp also said the narrow spot into which the car plunged at Kingston Mills locks is not a logical murder scene. There are easier places to submerge a car, he said, and better choices to make it look like an accident.

Court has heard evidence it appears the four made no attempt to escape the car through an open window, and the bodies were found eerily suspended inside.

Kemp suggested that’s plausible in an accident scenario.

“If it’s an accident then there’s no real panic until the vehicle all of a sudden isn’t on the ground anymore, it’s going in the water,” Kemp said.

“It’s pitch black, it’s raining, there’s no moon, there’s no stars…water is gushing in through a window. You would immediately become disoriented. You wouldn’t know where up was. You wouldn’t know where down was…They’d have been climbing all over each other trying to get out of the vehicle and they weren’t successful.”

Keep it Factual
Add CityNews Toronto as a trusted source on Google to see more local stories from us.

Top Stories

Weight-loss drugs shaping up to be a boon for grocers' pharmacy units

While discount stores have been a bright spot recently for major grocery chains, other units within their empires have been quietly seeing a sales boom: their pharmacies. And it's largely coming from rising sales of weight-loss drugs. The popularity of Ozempic and other GLP-1 drugs, traditionally used to manage Type 2 diabetes, has exploded in recent years thanks to their weight-loss side effects. And as cheaper, generic versions become more widely available, uptake is only expected to rise further. Semaglutides, or GLP-1s as they're sometimes called, are the active ingredient in drugs like Ozempic. For grocers that have pharmacy units, signs of that growth are already noticeable in their financial reports. Loblaw Cos. Ltd., which owns Shoppers Drug Mart and Pharmaprix, reported a roughly 40 per cent surge in GLP-1 sales in each of its last two quarters. "We are beginning to see the impact of GLP-1 drugs going generic. It's still very early, but the initial indications are encouraging," Per Bank, chief executive of Loblaw, told analysts on an earnings call in July. Loblaw executives are projecting double-digit growth for GLP-1 sales in 2027. Metro Inc.'s outgoing chief executive, Eric La Flèche, struck a similar note during its earnings call last month. Metro owns Jean Coutu pharmacies. "Demand fundamentals remain strong with early evidence of increased patient adoption and higher prescription volumes," he said. Loblaw reported its drug retail same-store sales grew 4.6 per cent in its latest quarter, while Metro's pharmacy same-store sales were up 4.8 per cent. Both outpaced same-store sales metrics for food. The gains were driven by the prescriptions category. Even though generic versions of the drug mean lower prices, the growth in volume is still a net positive. "As generic supply continues to build, we expect ongoing expansion of the GLP-1 category to drive low-teens volume and contribution growth," La Flèche told analysts. That's "indicating that higher volumes should more than offset a meaningful portion of the price pressure from generalization," Veritas analyst Kathleen Wong said in a note about Metro's quarterly results in August. "The resulting price deflation is therefore likely to pressure pharmacy same-store sales measured in dollars, but Metro’s early experience suggests that increased accessibility and prescription volumes can offset part of that pressure at the contribution level." Health Canada has so far approved three generic semaglutide products, and is continuing to review more — making the country the first among G7 nations to do so. These used to be called the drug of the rich, said Amar Singh, senior director and head of Canadian retail insights at Kantar. "This drug was expensive, and now, with the generics coming out, this is increasing penetration as the cost has come down and more people can afford it," he said in an interview. Half of the respondents in a Leger poll from March said insurance coverage or a lower-cost generic would increase their likelihood of using a GLP-1. More than half cited weight loss as their primary reason for taking the drug. At that time, eight per cent — or three million Canadians — were on prescription GLP-1s, the survey suggested. With generics increasingly available in the market, Singh said he expects uptake to rise to about 20 per cent over the next year or two. That surge comes as Loblaw and Metro are expanding their pharmacy networks. Loblaw expects to have opened about 200 stores over the last three years, and roughly half are pharmacies, Wong said. Meanwhile, Empire acquired nine Morelli’s pharmacies in Ontario last month that are already situated within some Longo’s grocery stores. Jo-Ann McArthur, president of Nourish Food Marketing, said the increasing popularity of weight-loss drugs could be an opportunity for grocers to tailor customer experiences, especially as attitudes toward food change among weight-loss drug users. For instance, she said grocers could suggest GLP-1-friendly foods and offer meal planning through their loyalty apps, offer health-care insights for those on and off drugs, streamline store shelf labelling and market items that are weight-loss drug friendly. Late last year, Loblaw launched an online weight-management program for people to connect with health care practitioners and see if they qualify for the drugs. "Where they make more money (is) by providing more services and more advice and just making it easier for the consumer to just stay loyal," she said. And it's not just about keeping GLP-1 users within the same ecosystem. "People who are on these drugs often are controlling the whole family's shopping and meal prep," she said. "If one person in a family is on a diet, the whole family is on a diet." This report by The Canadian Press was first published Sept. 13, 2026.

2h ago

Top Stories

Weight-loss drugs shaping up to be a boon for grocers' pharmacy units

While discount stores have been a bright spot recently for major grocery chains, other units within their empires have been quietly seeing a sales boom: their pharmacies. And it's largely coming from rising sales of weight-loss drugs. The popularity of Ozempic and other GLP-1 drugs, traditionally used to manage Type 2 diabetes, has exploded in recent years thanks to their weight-loss side effects. And as cheaper, generic versions become more widely available, uptake is only expected to rise further. Semaglutides, or GLP-1s as they're sometimes called, are the active ingredient in drugs like Ozempic. For grocers that have pharmacy units, signs of that growth are already noticeable in their financial reports. Loblaw Cos. Ltd., which owns Shoppers Drug Mart and Pharmaprix, reported a roughly 40 per cent surge in GLP-1 sales in each of its last two quarters. "We are beginning to see the impact of GLP-1 drugs going generic. It's still very early, but the initial indications are encouraging," Per Bank, chief executive of Loblaw, told analysts on an earnings call in July. Loblaw executives are projecting double-digit growth for GLP-1 sales in 2027. Metro Inc.'s outgoing chief executive, Eric La Flèche, struck a similar note during its earnings call last month. Metro owns Jean Coutu pharmacies. "Demand fundamentals remain strong with early evidence of increased patient adoption and higher prescription volumes," he said. Loblaw reported its drug retail same-store sales grew 4.6 per cent in its latest quarter, while Metro's pharmacy same-store sales were up 4.8 per cent. Both outpaced same-store sales metrics for food. The gains were driven by the prescriptions category. Even though generic versions of the drug mean lower prices, the growth in volume is still a net positive. "As generic supply continues to build, we expect ongoing expansion of the GLP-1 category to drive low-teens volume and contribution growth," La Flèche told analysts. That's "indicating that higher volumes should more than offset a meaningful portion of the price pressure from generalization," Veritas analyst Kathleen Wong said in a note about Metro's quarterly results in August. "The resulting price deflation is therefore likely to pressure pharmacy same-store sales measured in dollars, but Metro’s early experience suggests that increased accessibility and prescription volumes can offset part of that pressure at the contribution level." Health Canada has so far approved three generic semaglutide products, and is continuing to review more — making the country the first among G7 nations to do so. These used to be called the drug of the rich, said Amar Singh, senior director and head of Canadian retail insights at Kantar. "This drug was expensive, and now, with the generics coming out, this is increasing penetration as the cost has come down and more people can afford it," he said in an interview. Half of the respondents in a Leger poll from March said insurance coverage or a lower-cost generic would increase their likelihood of using a GLP-1. More than half cited weight loss as their primary reason for taking the drug. At that time, eight per cent — or three million Canadians — were on prescription GLP-1s, the survey suggested. With generics increasingly available in the market, Singh said he expects uptake to rise to about 20 per cent over the next year or two. That surge comes as Loblaw and Metro are expanding their pharmacy networks. Loblaw expects to have opened about 200 stores over the last three years, and roughly half are pharmacies, Wong said. Meanwhile, Empire acquired nine Morelli’s pharmacies in Ontario last month that are already situated within some Longo’s grocery stores. Jo-Ann McArthur, president of Nourish Food Marketing, said the increasing popularity of weight-loss drugs could be an opportunity for grocers to tailor customer experiences, especially as attitudes toward food change among weight-loss drug users. For instance, she said grocers could suggest GLP-1-friendly foods and offer meal planning through their loyalty apps, offer health-care insights for those on and off drugs, streamline store shelf labelling and market items that are weight-loss drug friendly. Late last year, Loblaw launched an online weight-management program for people to connect with health care practitioners and see if they qualify for the drugs. "Where they make more money (is) by providing more services and more advice and just making it easier for the consumer to just stay loyal," she said. And it's not just about keeping GLP-1 users within the same ecosystem. "People who are on these drugs often are controlling the whole family's shopping and meal prep," she said. "If one person in a family is on a diet, the whole family is on a diet." This report by The Canadian Press was first published Sept. 13, 2026.

2h ago

Most Watched Today